Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 7/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14272846 | 0.92 | CCR5 (0.46) | MEN1KMT2ATACR1CCR5ATM | |
| SCHEMBL4416844 | 0.91 | TACR1 (0.48) | MEN1KMT2ATACR1CCR5ATM | |
| SCHEMBL4160740 | 0.88 | TACR1 (0.48) | MEN1KMT2ATACR1CCR5ATM | |
| SCHEMBL17078067 | 0.86 | MEN1 (0.51) | MEN1KMT2ATACR1CCR5OPRD1 | |
| SCHEMBL4166875 | 0.86 | TACR1 (0.48) | TACR1CCR5ATMOPRD1OPRK1 | |
| SCHEMBL4542548 | 0.85 | TACR1 (0.49) | TACR1CCR5ATMOPRD1OPRK1 | |
| SCHEMBL10306289 | 0.85 | TACR1 (0.50) | MEN1KMT2ATACR1CCR5ATM | |
| SCHEMBL4414050 | 0.84 | CCR5 (0.53) | MEN1KMT2ATACR1CCR5ATM | |
| SCHEMBL19226428 | 0.82 | TACR1 (0.60) | TACR1CCR5ATMOPRD1OPRK1 | |
| SCHEMBL14272923 | 0.82 | CCR5 (0.49) | MEN1KMT2ATACR1CCR5ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940401-B1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-07-11 | — | — | EP | disclosed |
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC3R | MEN1 2115/4885KMT2A 1161/4885TACR1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.